Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have received a consensus rating of “Hold” from the ten ratings firms that are presently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, one has issued a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $6.7143.

Several research firms have weighed in on NMRA. Weiss Ratings reissued a “sell (d-)” rating on shares of Neumora Therapeutics in a report on Thursday, January 22nd. Mizuho set a $6.00 target price on Neumora Therapeutics in a research report on Monday, January 5th. William Blair upgraded Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 17th. Leerink Partners initiated coverage on Neumora Therapeutics in a report on Monday, January 12th. They set an “outperform” rating and a $8.00 price target for the company. Finally, Royal Bank Of Canada upgraded Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and boosted their price target for the company from $4.00 to $7.00 in a research note on Monday, December 1st.

Neumora Therapeutics Stock Performance

NASDAQ NMRA opened at $2.33 on Friday. The stock has a market cap of $389.32 million, a PE ratio of -1.59 and a beta of 2.49. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.85 and a current ratio of 6.85. The firm has a 50-day moving average of $2.74 and a 200-day moving average of $2.31. Neumora Therapeutics has a 52-week low of $0.61 and a 52-week high of $3.65.

Insider Buying and Selling at Neumora Therapeutics

In other news, insider Paul L. Berns sold 9,819 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $3.51, for a total value of $34,464.69. Following the completion of the sale, the insider owned 7,395,185 shares of the company’s stock, valued at approximately $25,957,099.35. The trade was a 0.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold a total of 23,387 shares of company stock worth $82,647 over the last three months. 26.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Neumora Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Legacy Private Trust Co. bought a new stake in Neumora Therapeutics in the 3rd quarter valued at about $25,000. Hsbc Holdings PLC bought a new position in shares of Neumora Therapeutics during the fourth quarter worth approximately $27,000. Virtu Financial LLC acquired a new stake in shares of Neumora Therapeutics in the third quarter valued at approximately $31,000. Fred Alger Management LLC acquired a new stake in shares of Neumora Therapeutics in the fourth quarter valued at approximately $40,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Neumora Therapeutics in the second quarter valued at approximately $41,000. 47.65% of the stock is owned by institutional investors.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.